NE · State regulatory reference
Nebraska.
Moderate
Nebraska is relatively permissive on telehealth and follows standard federal 503A compounding, with no distinctive state restriction or documented peptide/GLP-1 enforcement. Under Neb. Rev. Stat. § 38-1,143 (2019, amended 2021), a credential holder may establish a provider-patient relationship through telehealth and prescribe if otherwise authorized, and § 71-8506 provides that in-person contact is not required. Compounding under § 38-2867.01 requires USP <795>/<797> (as of Jan. 1, 2023) and bars compounding essentially copies of FDA-approved products — a restatement of federal 503A.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Neb. Rev. Stat. § 38-1,143 lets a provider establish the patient relationship and prescribe via telehealth (defined in § 38-120.01) with no blanket in-person exam requirement (§ 71-8506); § 71-8505 adds written-information and consent requirements before an initial telehealth consultation.
Compounding
Neb. Rev. Stat. § 38-2867.01 requires 503A compounding to meet USP <795> (nonsterile) and <797> (sterile) as they existed Jan. 1, 2023, and bars compounding copies of FDA-approved drugs; no GLP-1/semaglutide-specific Nebraska restriction was found.
Sources